Heart and Vessels

, Volume 29, Issue 1, pp 35–41 | Cite as

Low high-density lipoprotein cholesterol is a residual risk factor associated with long-term clinical outcomes in diabetic patients with stable coronary artery disease who achieve optimal control of low-density lipoprotein cholesterol

  • Manabu Ogita
  • Katsumi Miyauchi
  • Tadashi Miyazaki
  • Ryo Naito
  • Hirokazu Konishi
  • Shuta Tsuboi
  • Tomotaka Dohi
  • Takatoshi Kasai
  • Takayuki Yokoyama
  • Shinya Okazaki
  • Takeshi Kurata
  • Hiroyuki Daida
Original Article

Abstract

Diabetes mellitus is recognized an independent risk factor for coronary artery disease (CAD) and mortality. Clinical trials have shown that statins significantly reduce cardiovascular events in diabetic patients. However, residual cardiovascular risk persists despite the achievement of target low-density lipoprotein cholesterol (LDL-C) levels with statin. High-density lipoprotein cholesterol (HDL-C) is an established coronary risk factor that is independent of LDL-C levels. We evaluated the impact of HDL-C on long-term mortality in diabetic patients with stable CAD who achieved optimal LDL-C. We enrolled 438 consecutive diabetic patients who were scheduled for percutaneous coronary intervention between 2004 and 2007 at our institution. We identified 165 patients who achieved target LDL-C <100 mg/dl. Patients were stratified into two groups according to HDL-C levels (low HDL-C group, baseline HDL-C <40 mg/dl; high HDL-C group, ≥40 mg/dl). Major adverse cardiac events (MACE) that included all-cause death, acute coronary syndrome, and target lesion revascularization were evaluated between the two groups. The median follow-up period was 946 days. The rate of MACE was significantly higher in diabetic patients with low-HDL-C who achieved optimal LDL-C (6.9 vs 17.9 %, log-rank P = 0.030). Multivariate Cox regression analysis showed that HDL-C is significantly associated with clinical outcomes (adjusted hazard ratio for MACE 1.33, 95 % confidence interval 1.01–1.75, P = 0.042). Low HDL-C is a residual risk factor that is significantly associated with long-term clinical outcomes among diabetic patients with stable CAD who achieve optimal LDL-C levels.

Keywords

Low HDL-C Residual risk factor Diabetes Coronary intervention 

References

  1. 1.
    Kannel WB, McGee DL (1979) Diabetes and cardiovascular disease: the Framingham Study. JAMA 241:2035–2038PubMedCrossRefGoogle Scholar
  2. 2.
    Bloomgarden ZT (2008) Cardiovascular disease in diabetes. Diabetes Care 31:1260–1266PubMedCrossRefGoogle Scholar
  3. 3.
    Preis SR, Hwang SJ, Coady S, Pencina MJ, D’Agostino RB Sr, Savage PJ, Levy D, Fox CS (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 119:728–1735Google Scholar
  4. 4.
    Miettinen H, Lehto S, Salomaa V, Mahonen M, Niemela M, Haffner SM, Pyorala K, Tuomilehto J (1998) Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care 21:69–75PubMedCrossRefGoogle Scholar
  5. 5.
    Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRefGoogle Scholar
  6. 6.
    Nasu K, Tsuchikane E, Kato O, Fujita H, Surmely JF, Ehara M, Kinoshita Y, Tanaka N, Matsubara T, Asakura Y, Terashima M, Suzuki T (2008) Plaque characterization by Virtual Histology intravascular ultrasound analysis in patients with type 2 diabetes. Heart 94:429–433PubMedCrossRefGoogle Scholar
  7. 7.
    Mineoka Y, Fukui M, Tanaka M, Tomiyasu K, Akabame S, Nakano K, Yamazaki M, Hasegawa G, Oda Y, Nakamura N (2012) Relationship between cardio-ankle vascular index (CAVI) and coronary artery calcification (CAC) in patients with type 2 diabetes mellitus. Heart Vessels 27:160–165PubMedCrossRefGoogle Scholar
  8. 8.
    Farrag A, Bakhoum S, Salem MA, El-Faramawy A, Gergis E (2011) The association between extracoronary calcification and coronary artery disease in patients with type 2 diabetes mellitus. Heart Vessels. doi: 10.1007/s00380-011-0205-6
  9. 9.
    Flaherty JD, Davidson CJ (2005) Diabetes and coronary revascularization. JAMA 293:1501–1508PubMedCrossRefGoogle Scholar
  10. 10.
    Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Daida H (2008) Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Heart Vessels 23:149–154PubMedCrossRefGoogle Scholar
  11. 11.
    Colhoun HM, Bettteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH, on behalf of the CARDS investigators (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDs): multicenter randomized placebo-controlled trial. Lancet 364:685–696Google Scholar
  12. 12.
    Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 361:2005–2016PubMedCrossRefGoogle Scholar
  13. 13.
    Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256:2835–2838PubMedCrossRefGoogle Scholar
  14. 14.
    Sharrett AR, Ballantyne CM, Coady SA, Heiss G, Sorlie PD, Catellier D, Patsch W, Atherosclerosis Risk in Communities Study Group (2001) Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 104:1108–1113Google Scholar
  15. 15.
    The Committee of Japan Diabetes Society on the diagnostic criteria of diabetes mellitus (2010) Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. J Jpn Diabetes Soc 53:450–467Google Scholar
  16. 16.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285:2486–2497CrossRefGoogle Scholar
  17. 17.
    Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M (2007) Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 14:45–50PubMedCrossRefGoogle Scholar
  18. 18.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A, Collaborators developing the Japanese equation for estimated GFR (2009) Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 53:982–992PubMedCrossRefGoogle Scholar
  19. 19.
    The Examination Committee of Criteria for Metabolic Syndrome (2005) Definition and criteria of metabolic syndrome. J Jpn Soc Int Med 94:794–809 (in Japanese)CrossRefGoogle Scholar
  20. 20.
    Oda E, Watanabe K (2006) Japanese criteria of metabolic syndrome. Circ J 70:364PubMedCrossRefGoogle Scholar
  21. 21.
    Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB (2009) Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301:2129–2140PubMedCrossRefGoogle Scholar
  22. 22.
    Jacobs MJ, Kleisli T, Pio JR, Malik S, L’ltalien GJ, Chen RS, Wong ND (2005) Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 70:263–269PubMedCrossRefGoogle Scholar
  23. 23.
    Bruckert E, Baccara-Dinet M, Eschwege E (2007) Low HDL-cholesterol is common in European type 2 diabetic patients receiving treatment for dyslipidemia: data from a pan-European survey. Diabet Med 24:388–391PubMedCrossRefGoogle Scholar
  24. 24.
    Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC, Treating to New Targets Investigators (2007) HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357:1301–1310PubMedCrossRefGoogle Scholar
  25. 25.
    Goldbourt U, Yaari S, Medalie JH (1997) Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 17:107–113PubMedCrossRefGoogle Scholar
  26. 26.
    Miller M, Kwiterovich PO Jr (1990) Isolated low HDL cholesterol as an important risk factor for coronary heart disease. Eur Heart J Suppl H:9–14Google Scholar
  27. 27.
    Ueshima H, Iida M, Shimamoto T, Konishi M, Tanigaki M, Nakanishi N, Takayama Y, Ozawa H, Kojima S, Komachi Y (1982) High-density lipoprotein-cholesterol levels in Japan. JAMA 247:1985–1987PubMedCrossRefGoogle Scholar
  28. 28.
    Ko M, Kim MT, Nam JJ (2006) Assessing risk factors of coronary heart disease and its risk prediction among Korean adults: the 2001 Korea National Health and Nutrition Examination Survey. Int J Cardiol 110:184–190PubMedCrossRefGoogle Scholar
  29. 29.
    Heng D, Ma S, Lee JJ, Tai BC, Mak KH, Hughes K, Chew SK, Chia KS, Tan CE, Tai ES (2006) Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis 186:367–373PubMedCrossRefGoogle Scholar
  30. 30.
    Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H, The NIPPON DATA90 Research Group (2006) The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis 184:143–150PubMedCrossRefGoogle Scholar
  31. 31.
    Huxley RR, Barzi F, Lam TH, Czernichow S, Fang X, Welborn T, Shaw J, Ueshima H, Zimmet P, Jee SH, Patel JV, Caterson I, Perkovic V, Woodward M, for the Asia Pacific Cohort Studies Collaboration and the Obesity in Asia Collaboration (2011) Isolated low levels of high-density lipoprotein cholesterol are associated with an increased risk of coronary heart disease: an individual participant data meta-analysis of 23 studies in the Asia-Pacific region. Circulation 124:2056–2064PubMedCrossRefGoogle Scholar
  32. 32.
    Seo SM, Choo EH, Koh YS, Park MW, Shin DI, Choi YS, Park HJ, Kim DB, Her SH, Lee JM, Park CS, Kim PJ, Moon KW, Chang K, Kim HY, Yoo KD, Jeon DS, Chung WS, Park YG, Seung KB, Catholic University of Korea, Percutaneous Coronary Intervention Registry Investigators (2011) High-density lipoprotein cholesterol as a predictor of clinical outcomes in patients achieving low-density lipoprotein cholesterol targets with statins after percutaneous coronary intervention. Heart 97:1942–1950CrossRefGoogle Scholar
  33. 33.
    Betteridge DJ (2011) Lipid control in patients with diabetes mellitus. Nat Rev Cardiol 8:278–290PubMedCrossRefGoogle Scholar
  34. 34.
    Natarajan P, Ray KK, Cannon CP (2010) High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 55:1283–1299PubMedCrossRefGoogle Scholar
  35. 35.
    Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M (2010) Molecular mechanisms of HDL-cholesterol elevation by statins and its effects of on HDL functions. J Atheroscler Thromb 17:436–451PubMedCrossRefGoogle Scholar
  36. 36.
    Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B, ILLUMINATE Investigators (2007) Effects of toracetrapib in patients at high risk for coronary events. N Engl J Med 357:2109–2122PubMedCrossRefGoogle Scholar
  37. 37.
    Schwartz GG, Olsson AG, Abt M, Ballantyne CM, barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tradif JC, Wright RS, dal OUTCOMES Investigators (2012) Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 367:2089–2099Google Scholar
  38. 38.
    Investigators AIM-HIGH (2011) Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365:2255–2267CrossRefGoogle Scholar
  39. 39.
    Nichols GA, Vupputuri S, Rosales AG (2011) Change in high-density lipoprotein cholesterol and risk of subsequent hospitalization for coronary artery disease or stroke among patients with type 2 diabetes mellitus. Am J Cardiol 108:1124–1128PubMedCrossRefGoogle Scholar
  40. 40.
    Brown BG, Zhao XQ (2008) Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk. Am J Cardiol 101:58B–62BPubMedCrossRefGoogle Scholar
  41. 41.
    Hewing B, Fisher EA (2012) Rationale for cholesteryl ester transfer protein inhibition. Curr Opin Lipidol 23:372–376PubMedCrossRefGoogle Scholar
  42. 42.
    Scott R, O’Brien R, Fulcher G, Pardy C, D’Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, FIELD study investigators (2009) The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study. Diabetes Care 32:493–498PubMedCrossRefGoogle Scholar
  43. 43.
    Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, Faas FH, Anderson JW (2002) Diabetes, plasma insulin, and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med 162:2597–2604PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2013

Authors and Affiliations

  • Manabu Ogita
    • 1
  • Katsumi Miyauchi
    • 1
  • Tadashi Miyazaki
    • 1
  • Ryo Naito
    • 1
  • Hirokazu Konishi
    • 1
  • Shuta Tsuboi
    • 1
  • Tomotaka Dohi
    • 1
  • Takatoshi Kasai
    • 1
  • Takayuki Yokoyama
    • 1
  • Shinya Okazaki
    • 1
  • Takeshi Kurata
    • 1
  • Hiroyuki Daida
    • 1
  1. 1.Department of Cardiovascular MedicineJuntendo UniversityTokyoJapan

Personalised recommendations